Photo: Wikimedia Commons
GlaxoSmithKline pleaded guilty today to marketing its prescription antidepressants for uses never approved by federal regulators.As part of a plea agreement, Glaxo will pay $3 billion to settle a seven-year investigation into its drug marketing, Bloomberg reported Monday.
Glaxo fessed up to illicitly promoting its antidepressant Paxil for teens and children, and to advertising its depression drug Wellbutrin for weight loss.
Federal regulators didn’t approve of Paxil for teens or children or Wellbutrin for depression, making the marketing illegal.
The drug giant was also accused of concealing safety data about its diabetes drug Avandia from federal regulators, Bloomberg reported.
Glaxo’s conduct was the largest-ever case of health care fraud in the nation, Reuters reported.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.